Yin Zhidong, Sun Bohao, Wang Sisi, Xu Xi, Cheng Lu, Gao Yue, Jin Er
Department of Pathology, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China.
Department of Respiratory Medicine, Affiliated Hangzhou First People's Hospital, Westlake University, School of Medicine, Hangzhou, Zhejiang Province, China.
PeerJ. 2025 Feb 19;13:e18776. doi: 10.7717/peerj.18776. eCollection 2025.
This study aimed to investigate the role and expression patterns of IDO1 in various tumors, focusing on its correlation with clinical pathological characteristics and prognosis in patients specifically diagnosed with lung adenocarcinoma.
Pan-cancer analysis assessed IDO1 function across different tumor types. Bioinformatics tools, immunohistochemistry techniques, and statistical analyses were employed to evaluate IDO1 expression levels and their association with clinical pathological features and prognosis in patients with lung adenocarcinoma.
IDO1 was found to be significantly overexpressed in various types of tumors, with higher levels correlating with poorer progression-free survival (PFS) and overall survival (OS). In lung adenocarcinoma patients, IDO1 protein was predominantly localized to the cytoplasm and cell membrane of tumor cells, with higher expression observed in tumor cells closer to normal lung tissue. Statistical analysis revealed no significant differences in IDO1 expression based on the patient's clinical data, including gender, age, tumor location, allergy history, hypertension history, cardiovascular disease history, tumor history, diabetes (both type 1 and type 2), body mass index, smoking history, family history, alcohol history, and tumor maximum diameter ( > 0.05). However, IDO1 expression positively correlated with lymph node metastasis, pleural invasion, tumor recurrence, lower tumor differentiation, solid tumor components, preoperative chemotherapy, and clinical tumor, node, metastasis (TNM) staging (* < 0.05), while negatively correlating with prior surgical history (* < 0.05). Patients exhibiting high IDO1 expression levels demonstrated significantly worse PFS and OS (*** < 0.001 and ** = 0.003, respectively).
High IDO1 expression in lung adenocarcinoma correlates with increased tumor invasiveness, metastatic potential, advanced clinical stage, and poorer prognosis.
本研究旨在探讨吲哚胺2,3-双加氧酶1（IDO1）在各种肿瘤中的作用和表达模式，重点关注其与特定诊断为肺腺癌患者的临床病理特征及预后的相关性。
泛癌分析评估了IDO1在不同肿瘤类型中的功能。采用生物信息学工具、免疫组织化学技术和统计分析来评估IDO1的表达水平及其与肺腺癌患者临床病理特征和预后的关系。
发现IDO1在各种类型的肿瘤中显著过表达，水平越高与无进展生存期（PFS）和总生存期（OS）越差相关。在肺腺癌患者中，IDO1蛋白主要定位于肿瘤细胞的细胞质和细胞膜，在靠近正常肺组织的肿瘤细胞中观察到更高的表达。统计分析显示，基于患者的临床数据，包括性别、年龄、肿瘤位置、过敏史、高血压史、心血管疾病史、肿瘤史、糖尿病（1型和2型）、体重指数、吸烟史、家族史、饮酒史和肿瘤最大直径，IDO1表达无显著差异（>0.05）。然而，IDO1表达与淋巴结转移、胸膜侵犯、肿瘤复发、肿瘤低分化、实性肿瘤成分、术前化疗及临床肿瘤、淋巴结、转移（TNM）分期呈正相关（<0.05），而与既往手术史呈负相关（<0.05）。表现出高IDO1表达水平的患者的PFS和OS显著更差（分别为***<0.001和**=0.003）。
肺腺癌中IDO1高表达与肿瘤侵袭性增加、转移潜能、临床晚期及预后较差相关。
